Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Maravai LifeSciences Holdings, Inc. (MRVI)

NMS · Biotechnology

$6.86+0.17 (+2.54%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$2.53B
P/E (TTM)
EPS
$-0.73
Div Yield
52W Range
$1.99–$7.44
Beta
0.65

Company overview

Next earnings: 2026-08-06(9d)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Peers in Biotechnology

All in industry →

Recent press releases

Maravai LifeSciences Holdings, Inc. has not issued a press release in this window.

SEC filings

All filings →

Maravai LifeSciences Holdings, Inc. has not filed an SEC document in this window.

Maravai LifeSciences Holdings, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →

No 13F holdings have been reported for Maravai LifeSciences Holdings, Inc. in this window.

People at Maravai LifeSciences Holdings, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$18.1M
NI -$29.9M
06/25
$16.3M
NI -$39.6M
09/25
$41.6M
NI -$25.6M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.18
Prior: $-0.27
Revenue sparkline
MRVI (NMS) Stock Quote, Press Releases & SEC... | Cayman Journal | Cayman Journal